EU AI Act — Health-Threatening AI Technologies Banned, US Regulatory Contrast
OVERVIEWThe EU AI Act's prohibition on certain AI technologies deemed health-threatening came into effect this week, with the New York Post highlighting the stark contrast between the EU's proactive bans and the absence of equivalent US federal regulation. Prohibited categories include AI systems that exploit psychological vulnerabilities, enable social scoring, and certain forms of real-time biometric surveillance. In healthcare specifically, the Act's high-risk classification for AI systems used in medical diagnosis, patient management, and clinical decision support imposes conformity assessment requirements, transparency obligations, and post-market monitoring duties on EU-market products. These provisions apply regardless of where the AI system is developed. The US regulatory landscape remains fragmented, with the FDA's oversight limited to software meeting the definition of a medical device, and no comprehensive federal framework governing health AI broadly. This divergence is creating compliance complexity for multinational healthcare AI companies and raising equity questions about whether US patients have equivalent protections to their European counterparts. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.